Alnylam Pharmaceuticals Inc
ALNY328.160USD
-3.080-0.93%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
43.25BValor de mercado
1010.56P/L TTM
Mais detalhes de Alnylam Pharmaceuticals Inc Empresa
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Informações de Alnylam Pharmaceuticals Inc
Código da empresaALNY
Nome da EmpresaAlnylam Pharmaceuticals Inc
Data de listagemMay 28, 2004
CEOGreenstreet (Yvonne L)
Número de funcionários2230
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 28
Endereço675 W Kendall St
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142-1168
Telefone16175518200
Sitehttps://www.alnylam.com/
Código da empresaALNY
Data de listagemMay 28, 2004
CEOGreenstreet (Yvonne L)
Executivos da empresa Alnylam Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
78.82K
+9426.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.52K
+3413.00%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
29.73K
+2290.00%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+775.00%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
+775.00%
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
+775.00%
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
78.82K
+9426.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.52K
+3413.00%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
29.73K
+2290.00%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+775.00%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
+775.00%
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
AMVUTTRA
685.30M
54.87%
Regeneron Pharmaceuticals
326.60M
26.15%
GIVLAARI
73.87M
5.91%
OXLUMO
52.83M
4.23%
Other
48.80M
3.91%
Outro
61.62M
4.93%
Por RegiãoUSD
Nome
Receita
Proporção
United States
613.98M
49.16%
Net revenues from collaborations
351.74M
28.16%
Europe
172.67M
13.82%
Rest of World
64.43M
5.16%
Royalty revenue
46.20M
3.70%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
AMVUTTRA
685.30M
54.87%
Regeneron Pharmaceuticals
326.60M
26.15%
GIVLAARI
73.87M
5.91%
OXLUMO
52.83M
4.23%
Other
48.80M
3.91%
Outro
61.62M
4.93%
Distribuição de ações
Atualizado em: há 2 horas
Atualizado em: há 2 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.21%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
Outro
54.86%
Investidores
Investidores
Proporção
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.21%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
Outro
54.86%
Tipos de investidores
Investidores
Proporção
Investment Advisor
69.40%
Investment Advisor/Hedge Fund
23.27%
Hedge Fund
3.83%
Research Firm
2.50%
Sovereign Wealth Fund
1.70%
Pension Fund
1.30%
Bank and Trust
1.26%
Corporation
1.05%
Individual Investor
0.43%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
1441
132.38M
102.07%
-8.88K
2025Q3
1468
132.43M
102.39%
+2.53M
2025Q2
1335
129.81M
101.55%
+2.82M
2025Q1
1292
127.17M
99.72%
-2.77M
2024Q4
1248
125.34M
101.87%
-989.05K
2024Q3
1210
126.51M
99.20%
+3.13M
2024Q2
1165
122.70M
94.98%
+5.27M
2024Q1
1152
117.38M
97.56%
-6.00M
2023Q4
1149
120.10M
100.10%
-712.55K
2023Q3
1103
121.13M
101.32%
-503.11K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital World Investors
16.43M
12.44%
-370.75K
-2.21%
Sep 30, 2025
Fidelity Management & Research Company LLC
15.91M
12.04%
+854.66K
+5.68%
Sep 30, 2025
The Vanguard Group, Inc.
13.51M
10.22%
+267.08K
+2.02%
Sep 30, 2025
Capital Research Global Investors
7.22M
5.47%
+31.18K
+0.43%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.59M
4.98%
+52.87K
+0.81%
Sep 30, 2025
JP Morgan Asset Management
3.87M
2.93%
+2.07M
+115.83%
Sep 30, 2025
State Street Investment Management (US)
3.08M
2.33%
-91.63K
-2.89%
Sep 30, 2025
Baillie Gifford & Co.
2.79M
2.11%
-242.53K
-8.00%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.50M
1.89%
+100.47K
+4.19%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
Global X Genomics & Biotechnology ETF
6.48%
ProShares Ultra Nasdaq Biotechnology
5.81%
Invesco Nasdaq Biotechnology ETF
5.77%
Franklin Genomic Advancements ETF
5.35%
iShares Biotechnology ETF
5.07%
VanEck Biotech ETF
4.56%
American Century Focused Dynamic Growth ETF
3.76%
Goldman Sachs Future Health Care Equity ETF
3.42%
First Trust NYSE Arca Biotechnology Index Fund
3.33%
Invesco NASDAQ Next Gen 100 ETF
3.28%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção6.48%
ProShares Ultra Nasdaq Biotechnology
Proporção5.81%
Invesco Nasdaq Biotechnology ETF
Proporção5.77%
Franklin Genomic Advancements ETF
Proporção5.35%
iShares Biotechnology ETF
Proporção5.07%
VanEck Biotech ETF
Proporção4.56%
American Century Focused Dynamic Growth ETF
Proporção3.76%
Goldman Sachs Future Health Care Equity ETF
Proporção3.42%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.33%
Invesco NASDAQ Next Gen 100 ETF
Proporção3.28%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
